Healthcare / Medical DevicesTaiwan
$73.70
+0.20 (+0.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $149.3M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
14.3x
↓EV/EBITDA
8.2x
↓ROE
13.4%
↑Gross Margin
68.6%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.7%
FCF CAGR
+82.6%
FCF margin
17.4%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $835.9M · net income $169.4M · FCF $145.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $835.9M | $835.9M | $769.6M | $675.0M | $615.5M |
| Net Income | $169.4M | $169.4M | $151.1M | $-11.3M | $45.7M |
| EBITDA | $245.6M | $245.6M | $216.4M | $32.1M | $95.6M |
| EPS | — | — | 4.97 | -0.37 | 1.50 |
| Gross Margin | 68.6% | 68.6% | 69.5% | 68.2% | 60.4% |
| Operating Margin | 25.0% | 25.0% | 23.7% | 24.8% | 10.8% |
| Net Margin | 20.3% | 20.3% | 19.6% | -1.7% | 7.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.12 | 0.14 | 0.16 |
| Current Ratio | 3.16 | 3.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $145.3M | $145.3M | $151.8M | $149.3M | $23.9M |
| Returns | |||||
| ROE | 13.4% | 13.4% | 16.4% | -1.4% | 5.2% |
| Valuation | |||||
| P/E | 14.31 | 14.31 | 16.10 | — | 33.47 |
| EV/EBITDA | 8.17 | 8.17 | 10.05 | 35.97 | 15.00 |
| P/B | 1.99 | 1.99 | 2.64 | 1.64 | 1.75 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | 14.0% | 9.7% | — |
| EPS Growth | — | — | 1443.2% | -124.7% | — |
| Dividend Yield | 6.8% | 6.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.3%
Start / end P/E
n/dx → n/dx
EPS bridge
4.97 → n/d
Residual
-26.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.